Development of dissolution test method for a telmisartan/amlodipine besylate combination using synchronous derivative spectrofluorimetry

• Main Authors: Panikumar Durga Anumolu, Sirisha Neeli, Haripriya Anuganti, Sathesh Babu Puvvadi Ranganatham, Subrahmanyam Chavali Venkata Satya
• Format: Article
• Language: English
• Published: Universidade de São Paulo 2014-04-01
• Series: Brazilian Journal of Pharmaceutical Sciences
• Subjects: farmacêutica com associação/controle de qualidade; Teste de dissolução/forma farmacêutica com associação; Telmisartana; Besilato de anlodipino; Espectrofluorimetria/análise quantitativa
• Online Access: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502014000200329&lng=en&tlng=en

The dissolution process is considered an important in vitro tool to evaluate product quality and drug release behavior. Single dissolution methods for the analysis of combined dosage forms are preferred to simplify quality control testing. The objective of the present work was to develop and validate a single dissolution test for a telmisartan (TEL) and amlodipine besylate (AML) combined tablet dosage form. The sink conditions, stability and specificity of both drugs in different dissolution media were tested to choose a discriminatory dissolution method, which uses an USP type-II apparatus with a paddle rotating at 75 rpm, with 900 mL of simulated gastric fluid (SGF without enzymes) as the dissolution medium. This dissolution methodology provided good dissolution profiles for both TEL and AML and was able to discriminate changes in the composition and manufacturing process. To quantify both drugs simultaneously, a synchronous first derivative spectrofluorimetric method was developed and validated. Drug release was analyzed by a fluorimetric method at 458 nm and 675 nm for AML and TEL, respectively. The dissolution method was validated as per ICH guidance.